Description
CDX-301 is an investigational medication currently being studied in clinical trials for various advanced cancers, including colorectal cancer. It is being tested in combination with other treatments, such as CDX-1140 and pembrolizumab. The goal of these early-phase trials (Phase 1) is primarily to determine the safest dose of CDX-301 and to evaluate its safety and tolerability when given with other therapies. Researchers are also looking for early signs that the treatment might be effective. CDX-301 is not yet approved for use in colorectal cancer or any other cancer.
Mechanism of Action
CDX-301 is being studied in combination with CDX-1140, which targets CD40, a protein found on certain immune cells and cancer cells. The specific mechanism of action for CDX-301 itself is being investigated in these clinical trials. It is being evaluated in combination with other agents to see if it can enhance the immune response against cancer or work synergistically with other treatments.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.